Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
Date:1/29/2009

Thursday, February 5th, 10:00 a.m. EST

WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 5th, 2009 at 10:00 a.m. EST, to report third quarter fiscal year 2009 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 383-8008 for domestic calls and (617) 597-5341 for international calls. Participants must provide the following passcode: 88957320. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 22 Global Vision, the leader in,automated proofreading ... of the top 20 pharmaceutical companies have selected ... textual and artwork errors from,occurring in their packaging ... in a reduction of quality issues and,costs, along ...
... Micromet, Inc.,(Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune,diseases, today announced that it ... Thursday, November 6, 2008, at 9:00 am Eastern ... third quarter 2008 financial results.,Micromet anticipates releasing its ...
... CAMBRIDGE, Mass., Oct. 22 Karen Walton-Bowen, ... years experience in the,pharmaceutical and biotechnology industries, ... Senior Director, Biometrics. An expert in,clinical trials ... clinical,development across multiple therapeutic areas, Ms. Walton-Bowen,s,experience ...
Cached Biology Technology:Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 3Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 4Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics 2
(Date:4/20/2014)... the body,s master cells demonstrate a bizarre property ... a study published today from scientists at the University ... is one which may have application as wide-ranging as ... stretched will contract. For example, if one pulls on ... The opposite is also true: squeeze a material and ...
(Date:4/20/2014)... to treat lung, breast and pancreatic cancers also promote ... University of California, San Diego School of Medicine have ... surface of drug-resistant tumors that appears responsible for inducing ... cancer cells. , The findings, published in the ... Biology , may point to new therapeutic opportunities for ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... Among humans, making yourself smell more alluring than you really ... a complete perfume industry. However, it is a matter of ... dupe ant workers into believing them to be one of ... Science this week , researchers from the Centre for Social ...
... could render the AIDS virus vulnerable to attack by ... the Fred Hutchinson Cancer Research Center published in PLoS ... designing an effective AIDS vaccine, which is badly needed ... estimated at about 2.5 million per year worldwide. ...
... breakthrough in understanding the way atoms move across cell membranes ... development of new treatments for inflammatory diseases such as rheumatoid ... identified a previously unknown natural mechanism that opens ion channels ... into and out of cells through the naturally occurring ...
Cached Biology News:Smell-wars between butterflies and ants 2
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... TOPO Cloning is ... available for cloning PCR ... and Zero Blunt TOPO ... and activated with topoisomerase ...
Applications: ISH...
Biology Products: